NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $11.74 +0.46 (+4.08%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.10▼$11.8350-Day Range$9.42▼$12.6752-Week Range$6.07▼$17.02Volume861,466 shsAverage Volume750,385 shsMarket Capitalization$687.14 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Phathom Pharmaceuticals alerts: Email Address Phathom Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside87.4% Upside$22.00 Price TargetShort InterestBearish47.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 7 Articles This WeekInsider TradingSelling Shares$575,147 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.57) to ($4.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector480th out of 936 stocksPharmaceutical Preparations Industry220th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Phathom Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted47.12% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 20.5, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 2.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAT. Previous Next 3.1 News and Social Media Coverage News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest8 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows4 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $575,147.00 in company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($5.57) to ($4.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More PHAT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAT Stock News HeadlinesJuly 18, 2024 | insidertrades.comMolly Henderson Sells 4,325 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 18, 2024 | insidertrades.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells $127,759.72 in StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 7:04 PM | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on Phathom Pharmaceuticals (PHAT)July 21, 2024 | msn.comBiden Health Watch; Pediatrician Killed on Bike; Olympic Medical Team Gets UniformJuly 20, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at Needham & Company LLCJuly 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Terveystalo Oy (OtherTTALF)July 19, 2024 | marketwatch.comPhathom Gets Expanded FDA OK of Voquezna in Non-Erosive GERDJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | markets.businessinsider.comPhathom Pharma's Voquezna 10 Mg Gets FDA Approval For Non-erosive GERDJuly 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna’s NERD Indication Approval and Robust Sales ForecastJuly 19, 2024 | americanbankingnews.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at HC WainwrightJuly 19, 2024 | americanbankingnews.comAzmi Nabulsi Sells 10,901 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 19, 2024 | americanbankingnews.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells 33,848 Shares of StockJuly 19, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 5.8% After Insider SellingJuly 18, 2024 | globenewswire.comPhathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in AdultsJune 26, 2024 | seekingalpha.comPhathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating DelaysJune 7, 2024 | investorplace.comRide the Gamma Wave: 3 Stocks on the Verge of a Short SqueezeSee More Headlines Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$28.00 Low Stock Price Target$10.00 Potential Upside/Downside+93.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net MarginsN/A Pretax Margin-9,507.71% Return on EquityN/A Return on Assets-66.97% Debt Debt-to-Equity RatioN/A Current Ratio7.83 Quick Ratio7.80 Sales & Book Value Annual Sales$680,000.00 Price / Sales976.93 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-8.94Miscellaneous Outstanding Shares58,530,000Free Float44,428,000Market Cap$664.32 million OptionableOptionable Beta0.68 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Terrie J. Curran (Age 55)President, CEO & Director Comp: $1.22MMr. David A. Socks (Age 49)Co-Founder & Director Comp: $54.17kDr. Azmi Nabulsi M.D. (Age 64)M.P.H., Co-Founder & COO Comp: $888.9kMs. Molly Henderson CPA (Age 53)MBA, Chief Financial & Business Officer Comp: $777.76kDr. Aditya Kohli Ph.D. (Age 36)Co-Founder Comp: $319.65kMr. Paul CocjaChief People OfficerMr. Tom HarrisChief Development Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMr. Martin J. GilliganChief Commercial OfficerMore ExecutivesKey CompetitorsORIC PharmaceuticalsNASDAQ:ORICNkartaNASDAQ:NKTXInnovivaNASDAQ:INVAKaryopharm TherapeuticsNASDAQ:KPTIBioXcel TherapeuticsNASDAQ:BTAIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 19,500 shares on 7/26/2024Ownership: 0.196%LVW Advisors LLCBought 12,909 shares on 7/16/2024Ownership: 0.022%Terrie CurranSold 33,848 sharesTotal: $396,698.56 ($11.72/share)Azmi NabulsiSold 10,901 sharesTotal: $127,759.72 ($11.72/share)Molly HendersonSold 4,325 sharesTotal: $50,689.00 ($11.72/share)View All Insider TransactionsView All Institutional Transactions PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $9.13 at the beginning of the year. Since then, PHAT stock has increased by 28.6% and is now trading at $11.74. View the best growth stocks for 2024 here. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings results on Thursday, May, 9th. The company reported ($1.42) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.01. The company had revenue of $1.91 million for the quarter, compared to analyst estimates of $2.76 million. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.20%), Inspirion Wealth Advisors LLC (0.06%) and LVW Advisors LLC (0.02%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh and David A Socks. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK) and CenterPoint Energy (CNP). This page (NASDAQ:PHAT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
